Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, April 02, 2024 -- Arch Biopartners Inc., , announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and...